Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04346628 · ClinicalTrials.gov registry record · Phase 2
Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT04346628: Completed Phase 2 study, sponsored by Stanford University.
NCT04346628 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 149 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04346628, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.
Interventions
- DRUG Placebo
- OTHER Standard of care treatment
- DRUG Favipiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2020-07-12 |
| Est. Completion | 2021-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04346628
The ClinicalTrials.gov registry entry for NCT04346628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04346628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04346628 about?
NCT04346628 is a clinical study titled "Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19". The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.
What is the current status of trial NCT04346628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2020-07-12. Estimated completion is 2021-04-16.
What interventions are being tested in trial NCT04346628?
The interventions under investigation include: Placebo (DRUG), Standard of care treatment (OTHER), Favipiravir (DRUG).
Who is sponsoring clinical trial NCT04346628?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.